ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,768,284 | -73.3% | 333,010 | -52.0% | 0.00% | -100.0% |
Q2 2023 | $6,616,880 | +143.6% | 694,321 | +181.1% | 0.00% | 0.0% |
Q1 2023 | $2,716,736 | -34.4% | 246,976 | -11.7% | 0.00% | 0.0% |
Q4 2022 | $4,139,042 | +18.2% | 279,665 | +52.6% | 0.00% | 0.0% |
Q3 2022 | $3,503,000 | +70.9% | 183,297 | +90.6% | 0.00% | – |
Q2 2022 | $2,050,000 | +70.1% | 96,178 | +53.7% | 0.00% | – |
Q1 2022 | $1,205,000 | +20.5% | 62,573 | +29.7% | 0.00% | – |
Q4 2021 | $1,000,000 | +3.0% | 48,234 | +18.7% | 0.00% | – |
Q3 2021 | $971,000 | +12.1% | 40,627 | +27.9% | 0.00% | – |
Q2 2021 | $866,000 | +39.9% | 31,759 | +48.4% | 0.00% | – |
Q1 2021 | $619,000 | -90.2% | 21,397 | -90.5% | 0.00% | -100.0% |
Q4 2020 | $6,322,000 | +20.3% | 224,765 | +25.3% | 0.00% | +100.0% |
Q3 2020 | $5,256,000 | +1.1% | 179,376 | +4.3% | 0.00% | -50.0% |
Q2 2020 | $5,199,000 | -12.6% | 171,914 | -13.9% | 0.00% | 0.0% |
Q1 2020 | $5,949,000 | – | 199,630 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $296,569,000 | 22.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $111,937,000 | 7.03% |
Pivotal bioVenture Partners Investment Advisor LLC | 671,716 | $18,895,000 | 6.23% |
Omega Fund Management, LLC | 640,199 | $18,009,000 | 2.70% |
Orbimed Advisors | 6,073,850 | $170,857,000 | 1.50% |
Vivo Capital, LLC | 867,170 | $24,393,000 | 1.09% |
Octagon Capital Advisors LP | 100,000 | $2,813,000 | 0.98% |
Altium Capital Management LP | 62,962 | $1,771,000 | 0.66% |
RA Capital Management | 1,165,184 | $32,777,000 | 0.46% |
SILVERARC CAPITAL MANAGEMENT, LLC | 8,505 | $239,000 | 0.14% |